American Academy of Neurology 2026 (AAN)

Back

Zeleciment Basivarsen Targets the Underlying Cause of DM1 to Enable Functional Improvement in the Phase 1/2 ACHIEVE Trial

View

©2026 Dyne Therapeutics, Inc. All rights reserved MED-00978. Date of preparation: July 2026.